Back to search

Article

Assessing the cardiac safety of β-d-N4-hydroxycytidine (NHC) and Molnupiravir on hiPSC-Derived Cardiomyocyte Platform at Physiologically Relevant Concentrations

2026-07-25

Abstract excerpt

<title>Abstract</title> <p>Molnupiravir was approved by the U.S. Food and Drug Administration (U.S. FDA) in December 2021 for emergency use in adult patients infected with SARS-CoV-2 (COVID-19) who are at risk for progression to severe disease. While direct clinical evidence of Molnupiravir-induced cardiotoxicity is limited, its mechanism as a nucleoside analog raises theoretical concerns regarding mitochondrial...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ebef4002-0360-5570-b9b0-4c0ffaa19814
DOI
10.21203/rs.3.rs-10062738/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Assessing the cardiac safety of β-d-N4-hydroxycytidine (NHC) and Molnupiravir on hiPSC-Derived Cardiomyocyte Platform at Physiologically Relevant ConcentrationsDOI 10.21203/rs.3.rs-10062738/v1
Prediction of individualized cardiac safe dose of doxorubicin through integration of hiPSC-cardiomyocytes based in vitro testing and QSP-PK-TD modelSemantic proximity
Functional High Throughput Drug Screening Reveals Cyproheptadine as a Novel Treatment for <i>LMNA</i> -related CardiomyopathySemantic proximity
SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patientsSemantic proximity
In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessmentSemantic proximity
Use of hiPSC-derived cardiomyocytes to rule out proarrhythmic effects of drugs: the case of hydroxychloroquine in COVID-19Semantic proximity
Heart Slice Culture System Reliably Demonstrates Clinical Drug-Related CardiotoxicitySemantic proximity
Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathySemantic proximity
Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cellsSemantic proximity
Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.Semantic proximity
Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity
Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity ScreeningSemantic proximity
Assessment of potential SARS-CoV-2 virus integration into human genome reveals no significant impact on RT-qPCR COVID-19 testingSemantic proximity
Select a neighboring publication to make it the new centre.